Enodia Therapeutics
enodiatx.com
Biotechnology
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$22.4M
1 round on record
Latest round
$22.4M
Seed · Jan 2026 · 9 mo ago
The money's age
Fresh money
9 months since the last round · not hiring
Momentum
20/100
fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 11
Increased its share capital $8.2k · BODACC
Apr 15
New executive Enodia Therapeutics Appoints Dr. Yvonne McGrath as Chief Scientific Officer to Accelerate Upstream Targeted Protein Degradation Platform · enodiatx.com
Jan 8
Raised a round Seed $22.4M · led by Elaia · Nasdaq
Aug 20, 2025
Increased its share capital $1.5k · BODACC
2025
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Seed | Jan 2026 | $22.4M | Elaia lead, Pfizer Ventures lead, Bpifrance lead, Wallonie Entreprendre, Argobio Studio, MACSF, The Institut Pasteur, InvestSud, Sambrinvest, Mission BioCapital | Nasdaq |
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
We engineer neomorphic protein surfaces to unlock targeted protein degradation.
Pioneering Protein Degradation for Targeted Therapies. Laigo Bio is at the forefront of a revolutionary era in biotechnology -one that…
Treeline Biosciences is a biotechnology company developing small-molecule medicines for cancer and immune diseases.
KiloGen Therapeutics specializes in proximity pharmacology, molecular glues, targeted protein degradation (TPD), biotechnology, drug…
Discover the future of molecular glues with Coltac Therapeutics. Using a cutting-edge bacteria-based positive selection screening system…
Together we are transforming the future of Targeted Protein Degradation Our people are at the heart of our success Our commitment to…
News
Enodia Therapeutics Appoints Dr. Yvonne McGrath as Chief Scientific Officer to Accelerate Upstream Targeted Protein Degradation Platform
PARIS, April 15, 2026--Enodia Therapeutics, a biotechnology company developing small-molecule therapies targeting a unique form of protein degradation at the point of synthesis, appointed Yvonne McGrath, Ph.D. as Chief Scientific Officer. With over 25 yea
Read more
Report
Enodia Therapeutics Appoints Dr. Yvonne McGrath as Chief Scientific Officer to Accelerate Upstream Targeted Protein Degradation Platform
Supported by distinguished Scientific Advisory Board of industry and academic leaders in translational science and drug development PARIS - 15 April 2026 - Enodia Therapeutics, a biotechnology company developing small-molecule therapies targeting a unique
Read more
Report
Enodia Therapeutics Appoints Dr. Yvonne McGrath as Chief Scientific Officer to Accelerate Upstream Targeted Protein Degradation Platform
Read more
Report
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences
Enodia Therapeutics acquires Sec61 preclinical assets from Kezar Life Sciences to expand its targeted protein degradation platform and accelerate development of small-molecule inhibitors.
Read more
Report
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences
PARIS & SOUTH SAN FRANCISCO, Calif., March 12, 2026--Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, and Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical
Read more
Report
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences
PARIS& SOUTH SAN FRANCISCO, Calif.---- Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, and Kezar Life Sciences, Inc., a clinical-stage biotechnology company
Read more
Report
Enodia Therapeutics: €20.7 Million Seed Funding Closed To Advance SEC61-Based Small-Molecule Protein Degradation Platform
Enodia Therapeutics has raised €20.7 million (about $25 million) in a seed financing to advance a discovery platform that uses proteomics and machine learning to develop small molecules that degrade disease-driving proteins at the point of synthesis. The
Read more
Report
Enodia Therapeutics Secures €20.7M to Advance a Small-Molecule Platform for Targeted Protein Degradation Enabled by Proteomics and Machine Learning
PARIS, January 08, 2026--Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, today announced it has raised €20.7 million (US$25 million) in a Seed financing. Th
Read more
Report
Enodia Therapeutics Secures €20.7M to Advance a Small-Molecule Platform for Targeted Protein Degradation Enabled by Proteomics and Machine Learning
Enodia Therapeutics Secures €20.7M to Advance a Small-Molecule Platform for Targeted Protein Degradation Enabled by Proteomics and Machine Learning
Read more
Report
Enodia Therapeutics Secures €20.7M to Advance a Small-Molecule Platform
Enodia Therapeutics Secures €20.7M to Advance a Small-Molecule Platform for Targeted Protein Degradation Enabled by Proteomics and Machine Learning Seed round co-led by Elaia, Pfizer Ventures and Bpifrance Machine-learning platform enables signal peptide-
Read more
Report
Show more news
Financials
Total raised
$22.4M
Latest round
Seed
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Seed | 2026 | $22.4M | Details |